Memantine in Alzheimer's disease: Experience in an Alzheimer's disease assessment unit

Aging Clinical and Experimental Research

Volumn 24, Issue 2, 2012, Pages 193-196

  Sinforiani, Elena ^a   Pasotti, Chiara ^a   Chiapella, Laura ^a   Malinverni, Paola ^a   Zucchella, Chiara ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Alzheimer's disease; Long term treatment efficacy; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; PSYCHOTROPIC AGENT; RIVASTIGMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; ASTHMA; BRADYCARDIA; CONFUSION; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; NEUROPSYCHIATRY; OUTPATIENT; SCORING SYSTEM; SEIZURE; SIDE EFFECT;

EID: 84864515073     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/BF03325164     Document Type: Article

References (26)

1. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-asparatate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999; 38: 735-67. (Pubitemid 29187336)
2. Volbracht C, van Beek J, Zhu C, Blomgreen K, Leist M. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 2006; 23: 2611-22. (Pubitemid 43801453)
3. Winblad B, Poritis N. Memantine in severe dementia: results of the M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine. Int J Geriatr Psychiatry 1999; 14: 135-46. (Pubitemid 29110331)
4. Reisberg B, Doody R, Stoffler A et al. Memantine in moderateto-severe Alzheimer's Disease. N Engl J Med 2003; 348: 1333-41.
5. Calabrese P, Essner U, Förstl H. Memantine in clinical practice - results of an observational study. Dement Geriatr Cogn Disord 2007; 24: 111-7. (Pubitemid 47094070)
6. McShane R, Areosa-Sastre A, Minakaran N. Memantine for dementia (review). Cochrane Database Syst Rev 2006; 2: CD003154. DOI: 10.1002/14651858.CD003154. pub5
7. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer's Disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-7. (Pubitemid 46985287)
8. Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's Disease: post-hoc analysis of ADAS-cog and SIB total and single item scores from six randomised double-blind-placebo controlled studies. Int J Geriatr Psychiatry 2009; 24: 523-38.
9. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008; 23: 537-45. (Pubitemid 351722115)
10. Vidal JS, Lacombe JM, Dartigues JF et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiol 2008; 31: 193-200.
11. Waldemar G, Dubois B, Emre M et al. Recommendations for the diagnosis and management of Alzheimer's Disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007; 14: 1-26.
12. Tariot PN, Farlow MR, Grossberg GT et al. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomised controlled trial. JAMA 2004; 291: 317-24. (Pubitemid 38101604)
13. Rountree SD, Chan W, Pavlik N et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer's disease. Alzheimer's Res Ther 2009; 1: 7-14.
14. Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7.
15. McKeage K. Spotlight on memantine in moderate to severe Alzheimer's disease. Drugs Aging 2010; 27: 177-9.
16. Hort J, O'Brien T, Gainotti G et al, on behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010; 17: 1236-48.
17. Clerici F, Vanacore N, Elia A et al, and the Memantine Lombardy Study Group. Memantine in moderately-severe-to-severe Alzheimer's Disease. A postmarketing surveillance study. Drugs Aging 2009; 26: 321-32.
18. Mckhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44. (Pubitemid 14076461)
19. Folstein MF, Folstein, SE, McHugh PR. Mini Mental State; a practical method grading the cognitive status of patients for the clinician. J Psychiatry Res 1975; 12: 189-98.
20. Lawton MP. Scales to measure competence in every day activities. Psychopharmacol Bull 1988; 24: 695-7.
21. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-86.
22. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14. (Pubitemid 24382728)
23. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007; 120: 388-97. (Pubitemid 46627453)
24. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Longterm course and effectiveness of combination therapy in Alzheimer's disease. Alzheimer Dis Assoc Disord 2008; 22: 209-21.
25. Sinforiani E, Banchieri LM, Zucchella C, Bernasconi L, Nappi G. Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population. Funct Neurol 2003; 18: 233-7. (Pubitemid 38239687)
26. Sinforiani E, Zucchella C, Pasotti C, Bartolo M, Nappi G. Report of ten years' activity in an Alzheimer's Disease Assessment Unit. Aging Clin Exp Res 2009; 21: 365-8.